

**MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL  
VIRTUAL MEETING  
Monday October 24, 2022  
Minutes**

**Agenda Item 1**

**Call to Order:**

Co-chair Marc Nicole called the meeting to order at 2:00 PM. A quorum was present.

Executive Director York noted the absence of Board Chair Van Mitchell and introduced Marc Nicole and Lorraine Diana as Stakeholder Council Co-chairs.

**Stakeholder Council Members present:** Mandi Poplawski, Pharm.D., Shaun O'Brien, Sean Tunis, MD, MSc, Deron Johnson, Lorraine Diana, CRNP, Nicole Stallings, Hayley Park, Pharm.D., Marc Nicole, Sherita Hill Golden, MD, MHS, James Gutman, Beth Rada, John Elliott, Joseph Winn, Greta Kessler, Kimberly Robinson, Barry Lipsy

**Agenda Item 2**

**Opportunity for Public Comment**

No persons registered for an opportunity to provide public comment.

**Agenda Item 3**

**Approval of Minutes**

Co-chair Nicole asked for a motion to approve the August 22, 2022 minutes as submitted. Shawn Brown made a motion to amend Agenda Item 4 of the meeting minutes to include insulin products in the list of additional potential metrics. James Gutman seconded the motion to amend and the Stakeholder Council members unanimously approved the amendment.

**Action: AMENDMENT APPROVED**

Co-Chair Nicole asked for a motion to approve the August 22, 2022 minutes as amended. Barry Lipsy made a motion, which was seconded by James Gutman, and the Stakeholder Council unanimously approved the amended minutes.

**Action: MINUTES APPROVED WITH AMENDMENT.**

**Agenda Item 4**

**Cost Review Process**

Executive Director Andrew York provided an overview of the cost review process outlined in Health-General Article § 21-2C-09. Dr. York discussed potential methods that could be used to screen drugs and identify prescriptions for cost review in accordance with Health-General Article

§ 21-2C-08. Additional potential metrics include drugs with the highest overall spend, highest per-patient spend, highest patient out-of-pocket cost, highest price increase (percentage and gross), drugs reported by Maryland consumers as causing affordability issues, drugs approved through an FDA accelerated approval pathway, only drug in class, highest advertising spend, and longest patent extensions.

The presentation is available on the Board's website.

#### **Agenda Item 5**

##### **Legislative Update**

Health Policy Analyst Dr. Michelle Robinson provided an update on the Inflation Reduction Act and the provisions that impact prescription drug affordability, including its inflation penalty, insulin copay cap, Medicare part D reform, and Medicare prescription drug negotiation.

#### **Agenda Item 6**

##### **Administrative Update**

Dr. York advised that there will be a virtual stakeholder council meeting on December 19th, 2022. Executive Director York acknowledged stakeholder council co-chairs, Marc Nicole, and Lorianne Diana.

#### **Agenda Item 7**

##### **Chair's Update**

Co-chairs Nicole and Diana thanked the Stakeholder Council members for their work and participation.

Co-chair Nicole asked for a motion to adjourn the meeting. Nicole Stallings moved to adjourn and Barry Lipsy seconded the motion.

Meeting was adjourned at 3:22 PM.